Insys Therapeutics Reports Net Loss of $47 Million in Fourth Quarter

When it rains it pours, and for Insys Therapeutics, the rain seemingly never stops. On March 8, 2018, Insys released its financial report for the fourth quarter, and the full year ending on Dec. 31, 2017, and the results were less than stellar.

The company reported a quarterly net loss of approximately $47 million, or $0.65 per share, compared to the previous years loss of $3.7 million, or $0.05 cents per share. Adjusted EBITDA loss for the fourth quarter was $11.5 million, compared to the previous year’s Adjusted EBITDA of $6.1 million.

In response to the company’s rough financials, Piper Jaffray has downgraded Insys from Neutral to Underweight, with a price target of $4.00 and a 48% downside risk.

This is just the latest in a string of bad news for the beleaguered pharmaceutical company, which has been embroiled in scandal over the last several years due to unethical marketing practices related to its flagship product Subsys.

Most recently, the company was sued by New York Attorney General Eric Schneiderman over what he characterized as a pattern of deceptive and illegal conduct; including downplaying the risk of addiction, lying to healthcare providers, and bribing doctors to prescribe Subsys.

One such doctor, Gavin Awerbuch, was recently sentenced to 32 months in prison for participating in a fraudulent speaker program which paid him $138,435 in kickbacks. In addition to serving 32 months in prison, Awerbuch must pay $4.1 million in restitution and fines.

According to analyst David Amsellem, the company’s weak fourth quarter was largely due to a decline in sales of Subsys and this sentiment was largely echoed by Insys CEO Saeed Motahari.

“People are still reluctant to use this product even for appropriate patients that FDA has approved it,” Motahari said on a conference call, detailing the company’s earnings.

At the opening bell markets reacted strongly to the company’s weak financial report, with shares of Insys dropping off nearly 8% within the first few hours of trading.

William Sumner

William Sumner is a freelance writer specializing in the legal cannabis industry. You can follow William on Twitter @W_Sumner or on Medium.

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 2 days

Happy Friday! Marijuana Money July 23, 2021

@GreenMarketRpt – 3 days

RT : I spoke with to discuss cannabis stock options worth consideration, and why U.S. MSOs pique his interest…

Back to Top